REAL-WORLD SAFETY PROFILE OF TWICE-DAILY DEFERIPRONE FOR IRON OVERLOAD IN US PATIENTS WITH THALASSEMIA, SICKLE CELL DISEASE OR OTHER ANEMIAS.